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| INTRODUCTION
Ischemic events such as myocardial infarction (MI) and stroke are the main cause of morbidity and mortality in high income countries, and account for 15 million deaths per year worldwide. Undesired intravascular platelet activation at the site of endothelial injury plays a key role in the processes ultimately resulting in atherothrombosis with subsequent end organ damage. [1] [2] [3] Accordingly, antiplatelet therapy became a cornerstone in the secondary prophylaxis of adverse cardiovascular outcomes ( Figure 1 ). 4 Aspirin is the most popular antiplatelet agent in acute and long-term secondary prevention of ischemic events (Table 1) . 5 It exerts its inhibitory effect by irreversible acetylation of a serine residue of cyclooxygenase-1 and -2, thereby blocking synthesis of prostaglandin G2 and H2, and consequently thromboxane A2 generation ( Figure 1 ). 4 Large meta-analyses revealed a 20% reduction of atherothrombotic outcomes by aspirin in high-risk patients. 6, 7 Five adenosine diphosphate (ADP) P2Y 12 receptor antagonists have been approved for the clinical use in patients ( Figure 1 ) 8 : ticlopidine, clopidogrel, and prasugrel belong to the thienopyridine family and need to be metabolized by the hepatic cytochrome P450 enzyme system in order to become pharmacologically active and inhibit ADP-mediated platelet aggregation (Table 1) . 4, 9 Ticlopidine is not recommended by the current guidelines due to its many side effects. 10, 11 In contrast, clopidogrel plus aspirin is the state-of-the-art dual antiplatelet therapy (DAPT) following elective percutaneous coronary intervention (PCI) or peripheral angioplasty with stenting, 12 and prasugrel together with aspirin can be prescribed in acute coronary syndrome (ACS) patients undergoing PCI (Table 1) . 10, 11, 13 The triazolopyrimidine ticagrelor acts as a direct and reversible inhibitor at the ADP P2Y 12 receptor, 4 and has been approved in combination with aspirin for ACS patients without and with PCI (Table 1) . 10, 11 Cangrelor, an adenosine triphosphate analog, is an intravenous P2Y 12 antagonist directly and reversibly blocking the ADP receptor with a short half-life of 3 to 5 minutes. 4 Its administration together with aspirin is approved for PCI patients without prior P2Y 12 inhibitor treatment (Table 1) . 10, 11, 14 The group of glycoprotein (GP) IIb-IIIa antagonists comprises 3 agents ( Figure 1 ) 4 : abciximab, tirofiban, and eptifibatide are given intravenously in the peri-interventional setting to block platelet-to-platelet aggregation via the fibrinogen receptor on human platelets, 15 eg, in ACS patients with a high thrombotic burden or in case of a no reflow syndrome after PCI (Table 1) . 16 Finally, the thrombin receptor inhibitor vorapaxar prevents platelet activation by thrombin via protease-activated receptor (PAR)-1 on human platelets ( Figure 1 ). 4 Based on the results of the TRA 2P-
TIMI 50 (Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events -Thrombolysis in Myocardial
Infarction) trial in patients with stable atherosclerotic disease, 17 vorapaxar may be used in addition to standard antiplatelet therapy in the secondary prophylaxis of ischemic events in patients with a history of MI or symptomatic peripheral artery disease (PAD; Table 1 ).
Despite the advent of novel agents and major advances in antiplatelet treatment over the last decade, atherothrombotic events still impair the prognosis of many patients with cardiovascular disease.
Consequently, antiplatelet therapy remains a field of intense research and a large number of studies on its various aspects are published each year. This review article summarizes recent developments in antiplatelet therapy in cardiovascular disease focusing particularly on the duration of DAPT, new treatment regimens, the role of platelet function testing, and potential future targets of antiplatelet agents.
| DURATION OF DAPT
While the need for lifelong therapy with one antiplatelet agent, ie, aspirin or clopidogrel, is commonly agreed upon in patients who suffered an ischemic cardiovascular event, 6,7 the optimal duration of DAPT following an ACS and/or PCI with stent implantation is less well-established. Current guidelines recommend DAPT with aspirin and clopidogrel for 6 months following elective PCI with stent implantation, and DAPT with aspirin and prasugrel or ticagrelor for 12 months in ACS patients undergoing PCI and stenting. 10, 11 In the latter, clopidogrel should be prescribed instead of prasugrel or ticagrelor if the patient cannot be treated with one of the two newer ADP P2Y 12 inhibitors. Medically managed ACS patients should receive DAPT with aspirin and ticagrelor or-in case of an increased bleeding risk-clopidogrel for 12 months following the acute event. 10, 11 However, the duration of DAPT in the above-mentioned patient populations has recently been challenged by numerous clinical trials. In the DAPT study, 9961 patients who underwent PCI with drug-eluting stent implantation and were subsequently treated with aspirin plus clopidogrel or prasugrel for 12 months were randomly assigned to continue thienopyridine treatment or to receive placebo in combination with aspirin for another 18 months. 18 The coprimary efficacy end points were stent thrombosis and the composite of MI, stroke, or death during the period from 12 to 30 months. The primary safety end point was moderate or severe bleeding. The authors found that continued thienopyridine treatment significantly reduced both coprimary efficacy end points at the cost of a higher risk of moderate or severe bleeding in their patient population. 18 The benefits of longer-term DAPT were more evident in the ACS subgroup. 19 In the PEGASUS-TIMI to ticagrelor at a dose of 90 mg twice daily, ticagrelor at a dose of 60 mg twice daily, or placebo, and followed for a median of 33 months. 20 The primary efficacy end point was the composite of MI, stroke, or cardiovascular death, and the primary safety end point was TIMI major bleeding. Both ticagrelor regimens significantly reduced the primary efficacy end point but increased the rates of TIMI major bleeding (without increasing the risk of intracranial hemorrhage or fatal bleeding).
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F I G U R E 1 Platelet function and molecular targets of antiplatelet agents. Initial platelet adhesion to damaged vessel walls is mediated by the binding of exposed collagen to platelet surface glycoprotein (GP) VI and integrin α2β1 and by the binding of von Willebrand factor (VWF) to the platelet surface GPIb-IX-V complex. This complex is also a receptor for other platelet ligands (thrombospondin, collagen and P-selectin), leukocyte integrin αMβ2, and procoagulant factors (thrombin, kininogen, factor XI and factor XII). Thrombin, generated by the coagulation cascade, is a potent activator of human platelets through two platelet surface receptors: protease-activated receptor (PAR)-1 and PAR-4. In contrast to the DAPT study and the PEGASUS-TIMI 54 trial, several other studies investigated shorter DAPT regimens yielding promising results regarding the reduction of bleeding complications. 10 Prompted by the results from these previous trials, the DAPT score and the PRECISE-DAPT score were designed, 21, 22 and introduced in the 2017 Update on DAPT by the European Society of Cardiology (ESC) as risk stratification tools for ischemia and bleeding to determine the optimal duration of DAPT. 10 The DAPT score is calculated 12 months after uneventful DAPT and is comprised of 9 factors (age, heart failure/low left ventricular ejection fraction, vein graft stenting, MI at presentation, prior MI or PCI, diabetes, smoking, stent diameter <3 mm, paclitaxel-eluting stent) resulting in −2 to +10 points. 21 It was developed from patient data in the DAPT study 272) when they received 30 months of DAPT. 21 On the other hand, patients with a DAPT score <2 showed no reduction of ischemic events, but a higher bleeding risk (NNH 64) with prolonged DAPT. patients with a PRECISE-DAPT score ≥25 were exposed to a high bleeding risk by prolonged DAPT (NNH: 38) while gaining no ischemic benefit. 22 The guidelines therefore suggest limiting DAPT to 3 to 6 months in these patients, while patients with a score of ≤25 may benefit from 12 months or even further prolongation (up to 24 months) of DAPT. 10 In summary, the DAPT and PRECISE-DAPT risk scores represent a promising opportunity for a more individualized DAPT strategy to optimize protection from ischemia and minimize bleeding risk. However, both scores need to be evaluated prospectively in large populations of patients with different clinical manifestations of ischemic heart disease in order to draw definitive conclusions. As a cautionary note in ACS patients, the SMART-DATE (Safety of 6-month Duration of Dual Antiplatelet Therapy After Acute Coronary Syndromes) trial recently found a much higher rate of MI in ACS patients treated with 6 months of DAPT vs 12 or more months of DAPT. 25, 26 3 | NEW TREATMENT REGIMENS
| Dual vs triple antithrombotic therapy in patients with AF undergoing percutaneous coronary intervention
Oral anticoagulation (OAC) with direct oral anticoagulants (DOACs)
or vitamin K antagonists (VKAs) is the treatment of choice to avoid inhibitor (clopidogrel, prasugrel, or ticagrelor) were based on physician′s choice and had to be prespecified by the investigator before randomization. At 1 year, the primary end point of clinically significant bleeding had occurred significantly less frequently in dual and low-dose triple therapy with rivaroxaban as compared to conventional triple therapy with warfarin. The rates of cardiovascular death, MI, or stroke were similar in the 3 treatment groups.
However, as with the WOEST trial, PIONEER AF-PCI was underpowered to detect differences in ischemic outcomes. 30 In the RE- . 31 The duration of DAPT in the triple therapy group was 1 month in patients with bare metal stent implantation and 3 months in those receiving drug eluting stents, and therefore shorter than in PIONEER AF-PCI in which 22% of patients received 1 year of triple therapy. 30, 31 The primary end point of major or clinically relevant non-major bleeding was significantly reduced by both dual antithrombotic regimens compared with triple therapy over a mean follow-up of 14 months.
Analyzing both doses of dabigatran together, dual therapy with dabigatran was non-inferior to triple therapy regarding the composite efficacy end point of death, MI, stroke, systemic embolism, or unplanned revascularization (power of 83.6%). 31 However, the RE-DUAL PCI study was not adequately powered to prove noninferiority regarding the efficacy end point for the higher-or lower-dose dabigatran regimen alone vs triple therapy. Furthermore, the rate of stent thrombosis was numerically higher in patients randomized to dabigatran 110 mg twice daily plus ADP receptor antagonist compared with triple therapy, suggesting that the lower dose of dabigatran may only be used as part of a dual antithrombotic regimen in patients fulfilling dose reduction criteria and in those at very high bleeding risk. Of note, in both trials mainly clopidogrel was used as the ADP receptor antagonist in combined antithrombotic therapy:
in PIONEER AF-PCI only 4% to 7% of the patients in the three treatment groups received prasugrel or ticagrelor as the P2Y 12 inhibitor, 30 and in RE-DUAL PCI only 12% of patients were treated with ticagrelor. 31 at high bleeding risk. 32 Since large clinical trials of combined antithrombotic therapy with the two remaining DOACs, ie, apixaban and edoxaban, are currently ongoing, more data on bleeding and ischemic outcomes with dual vs triple therapy in AF patients undergoing PCI will be available in the near future.
| Combination of aspirin and rivaroxaban in stable atherosclerosis
The recently published COMPASS (Cardiovascular Outcomes for People Using Anticoagulation Strategies) trial compared standard antiplatelet therapy with low-dose aspirin (100 mg/day) vs rivaroxaban 2.5 mg twice daily plus aspirin or rivaroxaban 5 mg twice daily in 27 395 patients with stable coronary artery disease (CAD) and/or PAD. 34 Patients with CAD who were younger than 65 years of age were also required to have documentation of atherosclerosis involving at least two vascular beds or at least two additional risk factors (smoking, diabetes, chronic kidney disease with an estimated glomerular filtration rate <60 mL/min, heart failure, or nonlacunar ischemic stroke ≥1 month earlier). 34 The COMPASS trial was halted early after a mean follow-up of 23 months due to the superiority of the rivaroxaban-plus-aspirin regimen, including a lower rate of all-cause mortality. The primary composite outcome of MI, stroke, or cardiovascular death was significantly reduced by the combination of 2.5 mg rivaroxaban twice daily with low-dose aspirin compared with aspirin alone.
The end point reduction was mainly driven by a decrease in the rate of ischemic stroke and stroke of uncertain type as well as cardiovascular mortality in the overall study population, as well as in patients with CAD and PAD. [34] [35] [36] Furthermore, the rate of acute limb ischemia was significantly lower in both the rivaroxaban plus aspirin and the rivaroxaban only group in patients with PAD. 35 As with ischemic stroke, acute limb ischemia often has an embolic cause. Previous studies revealed an increased risk of AF in patients with atherosclerotic disease, in particular in PAD. 
| ROLE OF PLATELET FUNCTION TESTING
The response to antiplatelet therapy differs from one patient to the next, 42, 43 and in particular clopidogrel-mediated platelet inhibition is subject to considerable interindividual variations. 44, 45 Moreover, patients with high on-treatment residual platelet reactivity (HRPR) as assessed by platelet function tests are at an increased risk of ischemic outcomes post PCI. 46, 47 Increasing clopidogrel dosage as well as switching to prasugrel or ticagrelor decreases on-treatment platelet reactivity in patients with poor response to clopidogrel. [48] [49] [50] [51] However, the 
| FUTURE TARGETS OF ANTIPLATELET AGENTS

| P2Y 1 receptor
Currently available ADP receptor antagonists target only P2Y 12 , but not the second ADP receptor on human platelets, P2Y 1 ( Figure 1 ).
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Activation of P2Y 1 initiates ADP-induced platelet aggregation, and is responsible for platelet shape change, 65 while P2Y 12 activation leads to amplification and stabilization of the aggregation response. 66 A complex interplay between P2Y 1 and P2Y 12 has been described previously, 67 and coactivation of both seems essential for full platelet aggregation. 66, 68 for studies on antiplatelet efficacy (Table 2) . 66 GLS-409 significantly inhibited ADP-and collagen-induced platelet aggregation in rats and immediately attenuated platelet-mediated thrombosis in a canine model of ACS without affecting rat or canine hemodynamics. 66 Finally, GLS-409 effectively blocked agonist-stimulated platelet aggregation irrespective of concomitant aspirin therapy. 66 Thus, the dual antagonist of P2Y 1 and P2Y 12 ( Figure 1 ) may be a promising antiplatelet drug candidate, in particular for the initial phase of ACS. 
| Protease-activated receptors
The long half-life and slow off-rate are downsides of the approved PAR-1 antagonist vorapaxar. 70 Despite promising Phase II data, development of the PAR-1 antagonist atopaxar was halted. 71, 72 PZ-128 is a new cell-penetrating peptide-based inhibitor of PAR-1 which may overcome these limitations (Table 2) . 73 PZ-128 targets the receptor-G-protein interface on the inside surface of platelets thereby blocking downstream G protein signaling. PZ-128 has recently been shown to inhibit platelet activation rapidly and reversibly in animal models and in patients with CAD or with multiple risk factors for CAD, 73, 74 and may become useful for short-term inhibition of platelet aggregation, in particular in patients undergoing PCI.
Besides PAR-1, PAR-4 as second thrombin receptor on human platelets ( Figure 1 ) may serve as a target of new antiplatelet agents. 4, 70 Indeed, an orally active, selective, and reversible PAR-4 inhibitor named BMS-986120 yielded promising results in a nonhuman primate model as it exerted pronounced antithrombotic activity with only a minor prolongation of bleeding time (Table 2) . 75 In a subsequent phase I trial, Wilson et al. found BMS-986120 to be well-tolerated and to reduce substantially platelet-rich thrombus formation ex vivo. 76 
| Glycoprotein VI
Glycoprotein VI (Figure 1 ) is the major signaling receptor for collagen on human platelets with important functions in thrombosis and other platelet-mediated processes. 2 GPVI inhibitors that have previously been developed as potential antiplatelet drugs include the soluble GPVI-Fc fusion protein Revacept and inhibitory anti-GPVI antibodies. 70, 77, 78 More recently, hexa-and deca-peptides (Troα6 and Troα10) derived from the C-terminal region of the GPVI-specific agonist Tro (trowaglerix), which was purified from Tropidolaemus wagleri venom, 79 were shown to potently inhibit collagen-induced platelet aggregation without prolonging the bleeding time (Table 2) . 70, 80 The antiplatelet effect may be achieved by targeting of immunoglobulinlike domains of GPVI by Troα6 and Troα10. These small-mass hexa-/ deca-peptide GPVI antagonists have therapeutic potential in patients with cardiovascular disease. 80 Since activation of spleen tyrosine kinase (Syk) downstream of GPVI is crucial for platelet activation, 70 Syk inhibitors have also been investigated as possible antiplatelet agents. Van Eeuwijk et al.
reported that the orally available selective Syk inhibitor BI1002494
prevented arterial thrombosis and resulted in smaller infarct sizes and a significantly better neurological outcome 24 hours after transient middle cerebral artery occlusion in a mouse model (Table 2) . 81 
| Platelet oxidases
Lipoxygenases (LOXs) are enzymes catalyzing the oxygenation of polyunsaturated fatty acids which leads to the synthesis of various signaling molecules. 70 12-LOX is expressed in megakaryocytes and platelets, and oxidizes arachidonic acid at carbon 12. 82 Growing evidence suggests that 12-LOX is involved in platelet activation. [83] [84] [85] [86] Recently, Adili et al. studied the impact of the selective 12-LOX inhibitor ML355 on thrombosis and hemostasis (Table 2) . 87 They found a dose-dependent decrease of human platelet aggregation by ML355, an effect that was reversed after exposure to high concentrations of thrombin in vitro. Moreover, oral administration of ML355 in mice reduced thrombus formation and vessel occlusion in FeCl 3 -induced mesenteric and laser-induced cremaster arteriole thrombosis models with only minimal effects on hemostasis. 87 
| CONCLUSIONS
Recent data on abbreviated and prolonged DAPT challenged the current dogma on the optimal duration of combined therapy with aspirin and a P2Y 12 inhibitor after coronary stenting, 18, 20 and resulted in two new risk scores which may be used to individualize the duration of DAPT post PCI in patients at high risk of bleeding and ischemic events, respectively. 
